Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103323 · ClinicalTrials.gov registry record · Phase 3
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 760
- Enrollment target
NCT01103323 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 760 participants.
The verdict
NCT01103323, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 760 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC
Interventions
- DRUG Placebo
- OTHER Best Supportive Care (BSC)
- DRUG Regorafenib (Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103323
The ClinicalTrials.gov registry entry for NCT01103323 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 760 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01103323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103323 about?
NCT01103323 is a clinical study titled "Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy". This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC
What is the current status of trial NCT01103323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 760 participants. The study started on 2010-04. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01103323?
The interventions under investigation include: Placebo (DRUG), Best Supportive Care (BSC) (OTHER), Regorafenib (Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT01103323?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.